Barclays raised the firm’s price target on HCA Healthcare to $396 from $376 and keeps an Overweight rating on the shares post the Q2 report. HCA now expects volumes to double long-term averages and pointed to several sources of structurally higher demand, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA: